|
タカギ トシオ
Takagi Toshio
高木 敏男 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. |
| 掲載誌名 | 正式名：Japanese journal of clinical oncology 略 称：Jpn J Clin Oncol ISSNコード：03682811/14653621 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 51(4),pp.646-653 |
| 著者・共著者 | TACHIBANA Hidekazu†*, KONDO Tsunenori, ISHIHARA Hiroki, FUKUDA Hironori, YOSHIDA Kazuhiko, TAKAGI Toshio, IIZUKA Junpei, KOBAYASHI Hirohito, TANABE Kazunari |
| 発行年月 | 2021/04 |
| 概要 | PURPOSE:Combined immunotherapy of nivolumab plus ipilimumab for intermediate- and poor-risk metastatic clear cell renal cell carcinoma showed prolonged progression-free survival and high objective response rate in a randomized phase III clinical trial. However, the efficacy of this treatment for papillary renal cell carcinoma remains unclear. In the present study, we analysed the efficacy of nivolumab plus ipilimumab therapy for papillary renal cell carcinoma compared with that for clear cell renal cell carcinoma.MATERIALS AND METHODS:This is a retrospective study of 30 patients with metastatic renal cell carcinoma who received nivolumab and ipilimumab as first-line therapy between December 2015 and May 2020. The objective response rate, progression-free survival and toxicity were compared between the two groups (clear cell renal cell carcinoma and papillary renal cell carcinoma).RESULTS:Out of 30 patients, 7 and 23 were diagnosed with papillary renal cell carcinoma and clear cell renal cell carcinoma, respectively. With a median follow-up of 7.2 months, the median progression-free survival was significantly shorter in papillary renal cell carcinoma than in clear cell renal cell carcinoma (2.4 vs. 28.1 months, P = 0.014). Of the seven patients with papillary renal cell carcinoma, one had partial response, one had stable disease and five had progressive disease, resulting in an objective response rate of 14.2%, which was lower compared to that of clear cell renal cell carcinoma (14.2 vs. 52.1%, P = 0.06). Discontinuation due to toxicity was not observed with papillary renal cell carcinoma, meanwhile 60.8% of patient with clear cell renal cell carcinoma discontinued treatment due to toxicity.CONCLUSION:Nivolumab plus ipilimumab had modest efficacy for papillary renal cell carcinoma compared with that for clear cell renal cell carcinoma. Nivolumab plus ipilimumab remains an option for a limited number of patients with intermediate- or poor-risk papillary renal cell car |
| DOI | 10.1093/jjco/hyaa229 |
| PMID | 33212488 |